Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin

被引：1
|
作者：
Sahin, Mustafa [1 ]
Miskioglu, Mine [2 ]
Inanir, Isil [3 ]
Akar, Hikmet [1 ]
Nese, Nalan [4 ]
Temiz, Peyker [4 ]
Aydogdu, Ismet [2 ]
机构：
[1] Celal Bayar Univ, Fac Med, Dept Internal Med, Manisa, Turkey
[2] Celal Bayar Univ, Fac Med, Dept Hematol, Manisa, Turkey
[3] Celal Bayar Univ, Fac Med, Dept Dermatol, Manisa, Turkey
[4] Celal Bayar Univ, Fac Med, Dept Patol, Manisa, Turkey
来源：
TURKISH JOURNAL OF HEMATOLOGY | 2021年 / 38卷 / 01期
关键词：
Cutaneous anaplastic large cell lymphoma; Brentuximab; Monotherapy; Breast cancer;
D O I：
10.4274/tjh.galenos.2020.2020.0512
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：85 / 87
页数：4
相关论文
共 50 条
  • [31] Primary Cutaneous Anaplastic Large-Cell Lymphoma of the Eyelid
    Koestinger, Armin
    McKelvie, Penny
    McNab, Alan
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2012, 28 (01): : E19 - E21
  • [32] Primary Cutaneous Sarcomatoid Anaplastic Large-Cell Lymphoma
    Bassett, Katrina
    Stutz, Nathalie
    Stenstrom, Melissa L.
    Wood, Gary S.
    Fleming, Matthew G.
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2012, 34 (03) : 301 - 304
  • [33] Brentuximab Vedotin: A New Age in the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
    Minich, Stephanie S.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (03) : 377 - 383
  • [34] Complete Remission of a CD30-positive large-cell anaplastic Lymphoma under Therapy with Brentuximab Vedotin (Adcetris®)
    Drescher, C.
    Mickler, M.
    Berneburg, M.
    Haferkamp, S.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 17 - 17
  • [35] Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study
    Fukuhara, Noriko
    Yamamoto, Go
    Tsujimura, Hideki
    Chou, Takaaki
    Shibayama, Hirohiko
    Yanai, Tomoko
    Shibuya, Kazunori
    Izutsu, Koji
    LEUKEMIA & LYMPHOMA, 2020, 61 (01) : 176 - 180
  • [36] Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma
    Vaklavas, Christos
    Forero-Torres, Andres
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (04) : 209 - 225
  • [37] Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin
    Chen, Xueyan
    Soma, Lorinda A.
    Fromm, Jonathan R.
    ONCOTARGETS AND THERAPY, 2014, 7 : 45 - 56
  • [38] Primary cutaneous anaplastic large-cell lymphoma: A case report
    Abed, Kamil
    Stopa, Zygmunt
    Siewert-Gutowska, Marta
    MEDICINE, 2018, 97 (04)
  • [39] Primary cutaneous anaplastic large-cell lymphoma - Case report
    Rabello de Oliveira, Luciana Silveira
    Nobrega, Madeleyne Palhano
    Monteiro, Maira Gomes
    de Almeida, Wagner Leite
    ANAIS BRASILEIROS DE DERMATOLOGIA, 2013, 88 (06) : 132 - 135
  • [40] Primary cutaneous anaplastic large-cell lymphoma: a case report
    Cao, Can
    Zeng, Kang
    Wang, Menglei
    Han, Kai
    Peng, Yusheng
    Xiong, Hao
    Wang, Qi
    Li, Qian
    Wang, Qian
    Li, Li
    DERMATOLOGIC THERAPY, 2016, 29 (04) : 224 - 227
12345